• Media type: E-Article
  • Title: Endogenous estrogen receptor modulating oxysterols and breast cancer prognosis: Results from the MARIE patient cohort
  • Contributor: Decker, Nina Sophia; Johnson, Theron; Behrens, Sabine; Obi, Nadia; Kaaks, Rudolf; Chang-Claude, Jenny; Fortner, Renée Turzanski
  • imprint: Springer Science and Business Media LLC, 2023
  • Published in: British Journal of Cancer
  • Language: English
  • DOI: 10.1038/s41416-023-02315-w
  • ISSN: 1532-1827; 0007-0920
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:sec> <jats:title>Background</jats:title> <jats:p>27-hydroxycholesterol (HC) and 25-HC were identified as endogenous selective estrogen receptor modulators (SERMs) and estrogen receptor (ER) modulators, respectively. They are hypothesized to play a role in multiple physiologic processes and pathologies, including breast cancer development and progression.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We evaluated circulating 27-HC and 25-HC, and outcomes following a breast cancer diagnosis in 2282 women from the MARIE study over median follow-up of 11.6 years. 27-HC and 25-HC were quantified by liquid chromatography–mass spectrometry. We calculated hazard ratios (HR) and 95% confidence intervals [CI] using multivariable Cox Proportional Hazards regression.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>We observed no associations between 27-HC and breast cancer prognosis overall. Associations between 27-HC and survival differed by circulating estradiol concentrations and endocrine therapy, but not by hormone receptor status. Among women with estradiol levels below the median (0.08 nM), 27-HC was associated with higher risk of all-cause mortality (HR<jats:sub>log2</jats:sub> = 1.80 [1.20–2.71]) and breast cancer-specific mortality (HR<jats:sub>log2</jats:sub> = 1.95 [1.14-3.31]). No associations were observed in women with estradiol levels above the median. Higher 25-HC levels were associated with lower risk of recurrence (HR<jats:sub>log2</jats:sub> = 0.87 [0.77-0.98]).</jats:p> </jats:sec><jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Associations between 27-HC and breast cancer prognosis varied by circulating estradiol levels and endocrine therapy. Less consistent results were observed for 25-HC.</jats:p> </jats:sec>